Ferreira Nuno Dias, Caeiro Daniel, Adão Luís, Oliveira Marco, Gonçalves Helena, Ribeiro José, Teixeira Madalena, Albuquerque Aníbal, Primo João, Braga Pedro, Simões Lino, Ribeiro Vasco Gama
Department of Cardiology, Centro Hospitalar de Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal.
Pacing Clin Electrophysiol. 2010 Nov;33(11):1364-72. doi: 10.1111/j.1540-8159.2010.02870.x. Epub 2010 Aug 17.
Previous reports have suggested the occurrence of cardiac conduction disorders and permanent pacemaker (PPM) requirement after transcatheter aortic valve implantation (TAVI). Based on a single-center experience, we aim to assess the incidence of postprocedural conduction disorders, need for PPM, and its determinants after TAVI with a self-expanding bioprosthesis.
From August 2007 to October 2009, 32 consecutive patients underwent TAVI with the Medtronic CoreValve (MCV) System (Medtronic Inc., Minneapolis, MN, USA). Three patients paced at baseline and two cases of procedure-related mortality were excluded. We analyzed the 12-lead electrocardiogram at baseline, immediately after procedure and at discharge. Requirements for PPM were documented and potential clinical, electrophysiological, echocardiographic, and procedural predictors of PPM requirement were studied.
After TAVI, eight patients (29.6%) required PPM implantation due to high-grade atrioventricular (AV) block. The prevalence of left bundle branch block increased from 13.8% to 57.7% directly after implantation (P = 0.001). Need for PPM was correlated to the depth of prosthesis implantation (r = 0.590; P = 0.001). At a cutoff point of 10.1 mm, the likelihood of pacemaker could be predicted with 87.5% sensitivity and 74% specificity and a receiver operator characteristic curve area of 0.86 ± 0.07 (P = 0.003). Of the seven patients with preexisting right bundle branch block (RBBB), four (57.1%) required PPM implantation after TAVI.
High-grade AV block requiring PPM implantation is a common complication following TAVI and could be predicted by a deeper implantation of the prosthesis. Patients with preexisting RBBB also seem to be at risk for the development of high-grade AV block and subsequent pacemaker implantation.
既往报道提示经导管主动脉瓣植入术(TAVI)后可发生心脏传导障碍及需要植入永久性起搏器(PPM)。基于单中心经验,我们旨在评估使用自膨胀生物假体进行TAVI后术后传导障碍的发生率、PPM需求及其决定因素。
2007年8月至2009年10月,32例连续患者使用美敦力CoreValve(MCV)系统(美敦力公司,明尼阿波利斯,明尼苏达州,美国)进行TAVI。3例基线时起搏的患者及2例与手术相关的死亡病例被排除。我们分析了基线、术后即刻及出院时的12导联心电图。记录PPM需求情况,并研究PPM需求的潜在临床、电生理、超声心动图及手术预测因素。
TAVI后,8例患者(29.6%)因高度房室(AV)阻滞需要植入PPM。植入后左束支传导阻滞的发生率从13.8%直接增至57.7%(P = 0.001)。PPM需求与假体植入深度相关(r = 0.590;P = 0.001)。在截断点为10.1 mm时,预测起搏器需求的敏感度为87.5%,特异度为74%,受试者工作特征曲线面积为0.86±0.07(P = 0.003)。在7例术前存在右束支传导阻滞(RBBB)的患者中,4例(57.1%)TAVI后需要植入PPM。
需要植入PPM的高度AV阻滞是TAVI后的常见并发症,可通过假体更深的植入进行预测。术前存在RBBB的患者似乎也有发生高度AV阻滞及随后植入起搏器的风险。